Oxaliplatin-Gry Teva

Oxaliplatin, the active ingredient in Oxaliplatin-Gry Teva, is a platinum‑based chemotherapy presented as a sterile injectable solution for intravenous use. It is employed in the treatment of colorectal cancer and related solid tumours in adult patients. GNH USA supplies Oxaliplatin‑Gry Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin‑Gry Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic agent used primarily within the colorectal cancer treatment pathway.

- Colorectal cancer: enhances tumour response when combined with fluorouracil and leucovorin in adjuvant or metastatic settings. - Gastric cancer: contributes to tumour control as part of combination regimens. - Pancreatic cancer: used in multi‑drug protocols to improve progression‑free survival. - Ovarian cancer: added to standard chemotherapy to increase overall response rates. - Esophageal cancer: incorporated into combination therapy to augment tumour shrinkage. - Small‑cell lung cancer: employed in select protocols aiming to boost response rates.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, often dose‑dependent. - Nausea and vomiting: may occur during or after infusion. - Diarrhoea: typically mild to moderate. - Fatigue: generalized tiredness during treatment cycles. - Elevated liver enzymes: transient increase in transaminases. - Thrombocytopenia: reduced platelet count observed in blood tests.

Serious or Rare Side Effects: - Severe peripheral neuropathy: persistent sensory loss that may be irreversible. - Acute hypersensitivity reactions: flushing, rash, bronchospasm, or anaphylaxis. - Hemolytic‑uremic syndrome: rare but potentially life‑threatening kidney injury. - Severe neutropenia: marked drop in neutrophils increasing infection risk. - Cardiac arrhythmias: uncommon electrical disturbances during infusion. - Pulmonary toxicity: rare interstitial lung disease presenting with cough and dyspnoea.

Oxaliplatin should be administered with careful clinical oversight and patient monitoring.

- Renal function: assess baseline creatinine and adjust if impairment present. - Hepatic function: monitor liver enzymes before each cycle. - Neuropathy risk: evaluate pre‑existing neuropathy and adjust dose if needed. - Hematologic status: perform complete blood count prior to infusion. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Store at below 25°C: keep in original packaging, protect from light and moisture.

Oxaliplatin may interact with several concomitant medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Anticoagulants: increased bleeding risk during infusion. - Nephrotoxic agents: heightened renal toxicity when combined. - High‑dose vitamin C: may reduce platinum‑DNA binding effectiveness.

Moderate Interactions (Monitor Closely): - CYP450 inducers: potential alteration of drug clearance. - Immunosuppressants: additive bone‑marrow suppression. - Electrolyte‑altering diuretics: may affect renal handling of the drug.